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Abstract
Introduction: Health technology assessment (HTA) aims to 
provide decision makers with relevant data to make in-
formed choices. Recent changes in the Portuguese HTA 
framework have altered substantially the assessment meth-
odology with regard to economic evaluation, with potential 
impacts on access and process efficiency. The HTA Reshap-
ing Project had as its main objective informing the debate 
on HTA in Portugal, thereby identifying improvement op-
portunities and solutions to the HTA framework that address 
future challenges. Methods: The project comprised several 
phases, i.e., (1) mapping and evaluation of different HTA 
frameworks across Europe, identifying best practices and 
key variables to consider in future frameworks; (2) conduc-
tion of in-depth interviews with relevant stakeholders (n = 
11); and (3) development of 2 workshops – one with young 
professionals (n = 12) and another with relevant HTA stake-
holders (n = 19) – to consolidate and further explore vital 
elements of HTA, aimed at brainstorming ideas and develop-
ing solutions to improve some of the most critical points, 
with a view to addressing future challenges. Results: The 
comparison of HTA frameworks showed that their purpose 
and sophistication vary across European countries. For ex-
ample, the need for economic evidence is not unanimous, 
and reimbursement agreements vary considerably. Among 
the stakeholders interviewed there was a high level of agree-
ment on priorities that should be addressed, e.g., expanding 
and creating national level registries and assuring patient 
participation throughout the HTA process. The possibility of 
using managed entry agreements to enhance patients’ ac-
cess, applying multi-indication pricing for medicines with 
different therapeutic values per indication, and improve-
ment of registry/system interoperability gathered a moder-
ate level of agreement. Conclusions: The Portuguese HTA 
framework might be further adapted to upcoming challeng-
es and should evolve to improve access to innovative thera-
pies. There is still a long path towards the convergence of 
HTA frameworks in EU member states.
© 2021 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
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Resumo
Introdução: A avaliação de tecnologias da saúde (ATS) 
visa facultar aos decisores dados relevantes para a tomada 
de decisão. As recentes mudanças no quadro português 
de ATS alteraram substancialmente a metodologia de 
avaliação económica, com potenciais impactos no acesso 
e na eficiência dos processos. O Projecto HTA Reshaping 
teve como principal objetivo informar o debate sobre a 
ATS em Portugal, identificando oportunidades de melho-
ria e soluções para o enquadramento futuro da ATS. Mé-
todos: O projeto compreendeu várias fases: (i) Mapea-
mento e avaliação de diferentes estruturas de ATS na Eu-
ropa, identificando boas práticas e variáveis-chave a serem 
consideradas no futuro quadro de ATS em Portugal; (ii) 
Realização de entrevistas em profundidade com stake-
holders (n = 11); (iii) Desenvolvimento de dois workshops, 
um com jovens profissionais (n = 12) e outro com stake-
holders (n = 19), para consolidar e explorar os elementos 
fundamentais da ATS, com o objetivo de efetuar um brain-
storming de ideias e desenvolver soluções futuras para 
melhoria dos pontos mais críticos. Resultados: A compa-
ração das estruturas de ATS mostrou que seu propósito e 
sofisticação variam entre países europeus. A necessidade 
de evidência económica não é unânime e os acordos de 
financiamento variam consideravelmente. Entre os stake-
holders entrevistados, houve um elevado nível de con-
cordância sobre as prioridades, entre elas a expansão e 
criação de registros a nível nacional e a garantia de par-
ticipação dos doentes em todo o processo. A possibilidade 
de usar Managed Entry Agreements para melhorar o acesso 
dos doentes, aplicando Multi-Indication Pricing para medi-
camentos com diferente valor terapêutico por indicação e 
melhoria dos registros / interoperabilidade de sistemas 
reuniu um nível moderado de concordância. Conclusões: 
O quadro português de ATS pode ser adaptado aos desa-
fios futuros e deve evoluir para melhorar o acesso a ter-
apêuticas inovadoras. Ainda há um longo caminho para a 
convergência das estruturas de ATS nos estados-membros 
da UE. © 2021 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
Introduction
Innovative technologies have the potential to improve 
population outcomes. However, they are usually more ex-
pensive than the existing alternatives [1, 2]. This is a chal-
lenge to health systems around the world, which struggle 
with finite resources. Therefore, it is important to ensure 
that new technologies demonstrate value for money, i.e., 
that the health improvements brought about justify the ad-
ditional costs. Health technology assessment (HTA) is a 
systematic process for evaluation of health technologies to 
inform decision making [3]. HTA intends to inform deci-
sion makers about how to allocate resources effectively and 
efficiently. It is multidisciplinary and rooted in good prac-
tices in evaluation, including sound research methods. One 
of the key elements in HTA is economic evaluation, which 
aims to assess whether a health technology or intervention 
provides good value for money for the health service and 
the community. To evaluate value for money, it is usual to 
measure the differential in costs required to achieve an extra 
health benefit of a new therapy. Thus, HTA involves an as-
sessment of the properties, effects, and impacts of the tech-
nologies in terms of their efficacy or effectiveness as well as 
from the point of view of economic efficiency.
Australia was the first country to use these methods, in 
1993, followed by several OECD countries [4, 5]. In several 
countries HTA is used to define the health coverage of pro-
cedures, pharmaceutical products and equipment, and/or 
clinical guidelines. HTA agencies usually evaluate efficacy, 
effectiveness, and efficiency, while governments, insurance 
funds, or other third-party payers decide on whether the 
technology should be covered. The decision could be total 
coverage, partial coverage (with patient copayment or re-
striction to distinct indications/subpopulations) or cover-
age subject to new evidence development [4, 5]. At the Eu-
ropean level, HTA was traditionally developed within each 
country [6]. Recently, international networks, such as the 
EUnetHTA (European Network for Health Technology 
Assessment), have permitted the promotion of HTA 
knowledge sharing and the establishment of good practices 
and guidelines. However, despite the recent transnational 
collaborations, the purpose, frameworks, and sophistica-
tion of the methods used vary across countries [7]. 
HTA has been undertaken by public bodies in Portu-
gal for over 2 decades. It has been mandatory to deter-
mine the coverage of ambulatory drugs since 1999 (de-
cree-law No. 305/98) and for hospital drugs since 2007 
(decree-law No. 195/2006). Portugal became one of the 
first European countries to develop guidelines for HTA. 
They were published in 1998 (regulation 19064/99) [8]. 
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These guidelines were defined with pharmaceutical prod-
ucts in mind. However, evolution of HTA methodologies, 
international collaborations, and opportunities to incor-
porate real-world evidence along the product life cycle 
raised additional methodological challenges [9]. Recent-
ly, the Portuguese Commission for Health Technology 
Assessment (CATS) updated the Portuguese guidelines 
on economic evaluation, making various changes to the 
HTA methodology [10]. Among these were the proce-
dure for comparator selection, recommending multiple 
comparisons with all relevant alternatives, and the under-
lying evaluation perspective to be followed, moving from 
a stated preference for the societal perspective to one 
where only costs falling on the NHS are considered. These 
changes might affect access to new technologies. 
The aim of this article is to report on the results of the 
HTA Reshaping Project. This project aimed to establish 
a consensus based on expert opinion regarding future 
challenges in the assessment of pharmaceuticals and ac-
cess to new therapeutic alternatives (e.g., managed entry 
agreements [MEA], multi-indication pricing [MIP], as-
sessment of orphan medicines, patient-reported out-
comes [PRO], medicine reassessment, etc.), to assess the 
impact of potential changes to the current HTA process 
in Portugal, and to identify solutions to and/or improve-
ment opportunities for the HTA framework that would 
allow the mitigation of current/future challenges.
Methods
Study Design and Population
The methodology of the HTA Reshaping Project consisted of 
several phases: (1) mapping and evaluation of different HTA 
frameworks, identifying best practices and variables to consider in 
future frameworks; (2) conduction of in-depth interviews of rele-
vant stakeholders (n = 11); (3) development of 2 workshops – one 
with young professionals (n = 12) and another with relevant HTA 
stakeholders (n = 19) – to consolidate and further explore vital el-
ements of HTA, aimed at brainstorming ideas and developing so-
lutions to improve some of the most critical points, while prepar-
ing for future challenges. The starting point for the discussion in 
the workshops was provided by the results from phases (1) and (2). 
The methods for those phases are further detailed below.
Mapping and Evaluation of Different HTA Frameworks
A vital step in the early stages of the project was to carry out a 
literature review to examine the current situation and provide an 
overview of international best practices regarding HTA. Under-
standing the HTA landscape at the European level was an essential 
step to assess the convergence of the Portuguese HTA framework 
with comparable countries, i.e., other EU member states.
A nonsystematic literature review was performed to evaluate 
and compare the different HTA frameworks across Europe, fol-
lowed by identification of the future challenges mentioned in the 
literature. The review centered on economic aspects of HTA pro-
cesses, i.e., health economic evaluation methodologies and other 
associated themes such as pricing mechanisms and contracting. 
Regarding economic evaluation, a focus was placed on a set of key 
HTA parameters (comparators, population, therapeutic assess-
ment, time horizon, analytical methods, perspective, costs, PRO, 
and budget impact analysis).
In order to select comparable jurisdictions for benchmarking 
with Portugal, 3 sequential criteria were applied, i.e., region, econ-
omy/market dimension, and data availability. The regional filter 
was the first to be applied (i.e., Western Europe – the region to 
which Portugal belongs). The major economies and markets with-
in this region were selected for analysis. Hence, after assessing data 
availability for this set of countries, a final group of 7 major Euro-
pean economies (Belgium, France, Germany, Italy, the Nether-
lands, Spain, and the UK) and other relevant European countries 
(e.g., Nordic countries – Denmark, Finland, Norway, Sweden; oth-
er EU member states, and Switzerland) were selected for compar-
ison with the Portuguese setting.
Interviews
Several key Portuguese HTA stakeholders were interviewed to 
gather information on their insights regarding the current frame-
work and its future challenges. In-depth interviews were designed 
to understand the stakeholders’ position concerning the main top-
ics explored during the previous phase. This allowed identification 
of additional challenges and topics to be tackled in the future. Al-
though in-depth interviews are less structured than other qualita-
tive methods, they allow coverage of topics in great detail [11]. 
From the universe of topics explored during the interviews, a set 
of key aspects were selected according to their being mentioned a 
greater number of times by the interviewees. 
With the intention of engaging most organizations and stake-
holders that are either related to or have a profound knowledge 
and experience of Portugal’s HTA process, we sent out invitations 
to institutions asking them to appoint a representative to attend 
for interview or the later workshop (e.g., Ordem dos Farmacêuti-
cos, APIFARMA, APAH). In some cases, because the experience 
and interest of stakeholders in the subject is public and recognized, 
a direct invitation was made (e.g., Academia, INFARMED-CATS, 
Portuguese Health Economics Association, and patient associa-
tions). From these contacts, there emerged a subset of stakeholders 
that were willing and accepted to participate in one or more ac-
tivities comprising the research initiative. While this method does 
not guarantee a fully representative sample of organizations and 
stakeholders, we strived to achieve a balance of different view-
points relevant to the HTA landscape. 
The initial target was to carry out 10–15 interviews, and 11 
people agreed to participate. The group of stakeholders had a di-
verse composition, with 5 persons being drawn from academia, 2 
from the Portuguese Health Economics Association, and 4 from 
other sectors, such as the Executive Commission of CATS, ISPOR 
Portugal, and the pharmaceutical industry. 
Workshops
The following 2 workshops bringing together various stake-
holders were organized with a view to presenting the project’s pre-
liminary results and to brainstorm solutions and suggestions for 
mitigating the most critical HTA future challenges:
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 − HTA Junior Workshop. On November 12, 2019, a workshop 
was organized to gather insights from 12 young professionals 
(the initial target was 10–15 participants). These included 
members from universities, i.e., PhD students, members from 
the pharmaceutical industry, consultants, and professionals 
working in HTA-related projects. The main purpose of this 
workshop was to gather the point of view of young profession-
als involved in HTA-related themes who could possibly con-
tribute with fresh and innovative ideas that fall within the proj-
ect’s scope. This workshop was especially relevant since it al-
lowed assessment of the convergence/divergence of thoughts 
with HTA experts participating in the second workshop re-
garding the topics addressed in both sessions.
 − HTA Reshaping Workshop. On November 20, 2019, a second 
workshop was organized aimed at gathering insights from key 
stakeholders within the Portuguese HTA community. Of the 
initial target of 15–25 participants, 19 people agreed to partici-
pate. Stakeholders were selected given their important role in 
the HTA process in Portugal either presently or in the recent 
past. This workshop included 6 people from the pharmaceutical 
industry, 4 from academia, 3 professionals from relevant asso-
ciations (e.g., APAH, APIFARMA, Ordem dos Farmacêuticos), 
3 service providers or research centers (e.g., consultancy and 
research), 1 from the regulator (INFARMED), 1 from patient 
associations, and a person from other HTA-related professions. 
The selection criteria for the expert workshop is described in 
the previous subsection. Regarding the Junior workshop, partici-
pation was based on recommendations from academic stakehold-
ers (e.g., PhD and masters students and young researchers) and on 
self-registration following information disseminated in faculties. 
The discussion among HTA experts in the 2 workshops was 
intended to consolidate and further explore vital elements of HTA, 
aimed at brainstorming ideas and developing solutions to improve 
some of the most critical points, while preparing for future chal-
lenges. Thus, the questions addressed in the workshops emerged 
from the literature review and the in-depth interviews. 
The methodological approach used in the workshops is akin to 
an extended focus group, of which there are various examples in 
the literature (e.g., Timotijevic and Raats [12]). We chose not to 
use a Delphi type approach as it involves both qualitative and 
quantitative elements and because our objective was to get close to 
the participants’ understanding of and perspectives on particular 
issues rather than generation of generalizable data. Focus groups, 
in the extended form of a workshop, are helpful in identifying the 
thinking, perceptions, and impressions of a particular group [13].
Conclusions from the workshops were compiled by 4 authors 
(B.B., B.R., P.B.-C., and R.C.). These were classified according to 
the level of agreement as follows: high (accepted by all of the par-
ticipants), moderate (accepted by some), and low (accepted by 
only 1 participant).
Results 
Mapping and Evaluation of Different HTA 
Frameworks
The first phase of the project consisted of performing 
a literature review to evaluate and compare the different 
HTA frameworks across Europe. Some examples of the 
distinct features of drug evaluation in European countries 
are described below.
The purpose and sophistication of HTA frameworks 
vary across European countries. While most HTA bodies 
are aligned on the need for clinical evidence, the neces-
sity for economic evidence (particularly the requirements 
for budget impact and cost-effectiveness data) might dif-
fer. In some countries, such as France, budget impact 
analysis is not mandatory [14]. The HTA processes are 
also different regarding the choice of comparator. In the 
UK and the Netherlands, the comparator is the best cur-
rent alternative or treatment. In France, 3 comparators 
from the same therapeutic group are required, i.e., the 
most frequently used, the cheapest, and the most recently 
added to the positive list [15]. 
These different HTA practices in EU countries might 
result in conflicting decisions. A previous study identified 
a low alignment between HTA processes and recommen-
dations [16]. For new active substances approved by the 
EMA (2008–2012), only 6 out of 28 pairs of countries’ 
decisions were evaluated as highly congruent (the per-
centage of congruent recommendations for the total 
number of medicines reviewed by both jurisdictions was 
equal to or higher than 75%). These were also the coun-
tries that have separate agencies or organizations per-
forming the regulatory, HTA and decision-making func-
tions. Although the HTA recommendations were aligned 
according to the system type, the results were less aligned 
according to the HTA process type. According to the au-
thors, these discrepancies might also be explained by the 
quality of evidence used, the level of uncertainty accep-
tance, and the different methods of assessment or priori-
ties.
Portugal is more aligned with the UK and Nordic and 
Flemish countries. These countries use cost-effectiveness 
analysis methods to inform pharmaceutical access. In the 
UK, the cost-effectiveness threshold is explicitly set at 
GBP 20,000/QALY to GBP 30,000£/QALY [17], while no 
other country has an explicit threshold. Nevertheless, 
agreements on price or volume caps represent an infor-
mal way of implementing “affordability thresholds” [18]. 
Reimbursement agreements vary considerably be-
tween countries. In France, reimbursement agreements 
between the state and insurers might be based on results 
or price-volume agreements and with a sales cap [19]. In 
the Netherlands, drugs are subject to an approval process 
and a maximum price is defined for which the medicines 
are reimbursed [20]. In Belgium, the reimbursement 
agreements schemes might be based on price-volume, ev-
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idence, caps on costs, and portfolio approaches [21]. In 
Italy, reimbursement assessment is based on clinical and 
pharmacoeconomic data, itself grounded on an innova-
tion algorithm. Managed entry agreements are the main 
reimbursement mechanisms, with agreements based on 
results and costs [22]. In the UK, clinical outcomes and 
other information are available through a database, and 
reimbursement agreements are based on results and on a 
cap based on cost or revenues [23]. The HTA process in 
Spain is more complex due to decentralization of the 
health system. The autonomous regions are obliged to 
include in their reimbursement list any drug in the No-
menclatór and they can add different drugs to each re-
gional list. The reimbursement agreements between the 
state and insurers might be based on results and price-
volume, 2-tier pricing, and coverage with real-world evi-
dence development [24]. Finally, in Portugal, hospital 
products are fully covered and regarding pharmacy drugs 
a percentage of their price is reimbursed depending on 
the pharmacotherapeutic category, with a special scheme 
for pensioners and people with chronic diseases. In some 
cases, an economic assessment with a cost-effectiveness 
ratio might be required. The reimbursement agreements 
are based on price-volume, results, discounted prices, and 
risk-sharing [25].
Countries face a challenge to balance innovation with 
affordability. Flume et al. [18] describe in detail some ap-
proaches in European countries. They report a high vari-
ability across countries, each combining several tools 
adapted to their health system characteristics, such as “af-
fordability thresholds,” price-volume agreements or caps 
on individual product sales, and special budgets for in-
novative drugs. However, each strategy has its own draw-
backs and there is no “one size fits all” approach. For ex-
ample, innovation specific funds accelerate patient access 
but often represent a higher level of expenditure.
In order to increase access while simultaneously guar-
anteeing affordability, different European countries are 
currently using 3 different strategies of MIP [26]. The 
Netherlands opted to establish a price for the first indica-
tion, which is used to anchor the price of all further indi-
cations. If further indications are not cost-effective, either 
a lower price is negotiated, or the medicine may not be 
reimbursed. Another possible strategy is use of a weight-
ed price across all indications. This is the case of Germa-
ny, which negotiates the price for each new indication. 
Those negotiations are then reflected in a final common 
price. In France, the individual negotiations for each in-
dication are scored according to the therapeutic benefit 
and the public price reflects the weighting of the indica-
tion per expected volume. Belgium applies price reduc-
tions corresponding to one third of the spending increase 
due to multiple indications divided by the new spending 
volume. The third approach is setting of a different price 
for each indication. This is the case of Italy, which uses a 
large registry with individual patient data. Finally, the UK 
reviews each indication separately and they are only rec-
ommended if they are shown to be cost-effective. Despite 
the appealing characteristics of MIP, it entails several 
drawbacks. With the increased access, MIP can ultimate-
ly increase expenditures and pose a heavier administra-
tive burden, as it requires detailed information and can 
increase the risk of arbitrage if the drug is used in the 
higher-value indication at the lower-value indication’s 
price.
European HTA frameworks do not cover the full scope 
of gene and cell therapies. These new therapies may cure 
severe and life-threatening diseases but they may threaten 
health system sustainability. However, due to small pa-
tient populations and the distinct aspects of these thera-
pies it is difficult to produce robust clinical evidence to 
meet traditional HTA guidelines [27]. European coun-
tries might have to consider specific HTA methods to re-
flect the uncertainty using population level health effects 
and to consider different payment mechanisms.
Despite international networks recently developed to 
promote HTA knowledge sharing and the establishment 
of good practices and guidelines, the purpose, frame-
works, and sophistication of the methods used vary across 
European countries. Countries are heterogeneous and 
implement different HTA methods, and recommenda-
tions for new medicines also differ. Also, they face the 
emergence of future challenges such as new agreements 
methods and alternative pricing strategies and reim-
bursement mechanisms (e.g., MEA and MIP). In this 
context, it is still unclear whether HTA frameworks across 
Europe are converging and, particularly, whether Portu-
gal is converging with Europe.
In-Depth Interviews
Several key Portuguese HTA stakeholders were inter-
viewed to gather information about their insights regard-
ing the existing framework and its future challenges. The 
interviews were directed at 11 stakeholders, selected due 
to their relevant role in the HTA process, in the present 
or in the recent past. The results from the interviews are 
detailed in the following paragraphs (see online suppl. 
Appendix 1 for details about topics covered in the inter-
views; see www.karger.com/doi/10.1159/000516501 for 
all online suppl. material).
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Pharmacoeconomic Assessment Guidelines. The inter-
viewees recognized that the Portuguese HTA process is 
based on solid legislation when compared to other Euro-
pean countries. They pointed out that the use of real-
world evidence needs to be promoted and supported by 
adequate databases, such as the Registo Oncológico Na-
cional (RON) or SI.VIDA.
Most of the interviewees agreed that the societal per-
spective is more comprehensive than the NHS perspec-
tive and thus more beneficial since it broadly captures the 
entire benefits of drugs for the whole of society. However, 
it comes with methodological challenges, i.e., with regard 
to accurate measurement of all of the relevant costs for 
the appraisal. Since the nature of the included costs re-
flects the adopted perspective, current guidelines only re-
quire the inclusion of direct costs impacting the NHS. 
The interviewees suggested that other indirect costs (such 
as transportation, nonmedical costs, or productivity 
costs) could also be relevant despite being difficult to 
measure.
The stakeholders referred that pharmacoeconomic 
models for evaluating drugs are becoming increasingly 
complex and sophisticated, which does not necessarily 
mean they are leading to better results. The requirement 
of more tailor-made models might increase data needs 
and make the interpretation of results more difficult, i.e., 
for the general public.
HTA Process for Medical Devices. Creation of a lean 
HTA process for Medical Devices comprises multiple 
challenges such as defining clear assessment criteria for 
distinct types of devices (e.g., prostheses, ophthalmologi-
cal devices, breast implants, or pacemakers). However, 
the urgency to implement an HTA process for devices 
was consensual across the stakeholders. This process 
needs to be complemented with appropriate information 
systems and databases.
Patient Participation in the HTA Process. It was unan-
imous that patients’ participation in the HTA process is 
vital. Patients are crucial for contributing with systematic 
measurement of outcomes (PRO) for defining which out-
comes should be measured and how clinical endpoints 
should be assessed. Such participation could be assured 
either through the patient’s associations or by individual 
patient involvement. The added value of such participa-
tion would be in providing a patient-centered perspec-
tive, with insightful perspectives on the main challenges 
of the treatment and living with the disease, and percep-
tions of comparison with the standard of care. The way to 
incorporate them into the process is, however, less clear, 
according to the stakeholders. PRO may ultimately lead 
to a challenge on weighting the relative importance of 
each stakeholder and gathering data for certain groups of 
patients (e.g., how would these outcomes be measured for 
children or people with dementia?). To fully explore the 
potential of PRO, it is crucial to further develop current 
information systems to include this feature. One inter-
viewee mentioned the potential of pharmacies in gather-
ing data and creating real-time evidence. 
Assessing Drugs with Immature Data. Conditional ap-
proval of drugs was not consensual among all stakehold-
ers. Approval of drugs based on immature data compris-
es several challenges, i.e., the trade-off between assuring 
access and the uncertainty regarding drugs’ efficacy and 
safety. The stakeholders recognized that the generation of 
real-world evidence might be useful and also raised great 
concerns regarding potential safety issues arising from 
decision making based on immature data.
Multi-Indication Pricing. MIP can be a useful mecha-
nism to foster research and development for additional 
indications. Nevertheless, it could limit a given drug’s us-
age among certain subpopulations and/or increase patient 
discrimination. Some interviewees perceived MIP as un-
ethical. To minimize this negative effect of price discrim-
ination, proper audits to prescription tracking for drugs 
using MIP should be performed. Another identified chal-
lenge was prescription tracking for different indications 
given that it is difficult to monitor whether physicians are 
prescribing a certain drug for the right indication. The 
stakeholders referred that price discrimination must be 
supported by adequate registries for each indication. 
Assessing Drug Combinations. Currently, drug combi-
nations are assessed as the sum of products, evaluated sep-
arately. The assessment of drug combinations might be 
beneficial since they might incorporate synergies of using 
both products in combination. A major challenge that 
may arise from assessing these drug combinations are sit-
uations in which 2 different companies are involved. 
Drug Reassessments. Drug reassessment is one of the 
major topics requiring improvement according to most in-
terviewees, being particularly relevant for medical devices 
and situations where the evidence available during the as-
sessment phase is weak and/or limited. Gathering real-
world evidence to support reassessments could represent a 
significant challenge in terms of workload for institutions, 
such as hospitals. Additionally, another challenge is the 
identification of which data would need to be collected. 
Workshops
Two workshops were then performed to discuss the 
main conclusions from the previous phases. The young 
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professionals’ workshop aimed to discuss innovative 
ideas, promote the discussion of some of the most rele-
vant HTA-related challenges, and develop possible solu-
tions. The expert’s workshop proposed discussion of the 
topics that require more expertise, gathering insights 
from renowned stakeholders within the HTA commu-
nity. The main topics discussed are presented in Tables 1 
and 2.
HTA Junior Workshop
The workshop gathered 12 young professionals in-
volved in the HTA process in Portugal. 
MEA and MIP. These methods might be a relevant 
mechanism to improve access. However, they should be 
supported by an improved registry database. Participants 
identified the possibility of these databases being (par-
tially) funded by the pharmaceutical industry. MIP im-
plementation must be assured by accurate prescription 
tracking. 
HTA Process in Portugal from 1998 to 2019. The change 
in pharmacoeconomic guidelines from the societal to the 
NHS perspective provides no incentive to measure indi-
rect costs and those costs that have no impact on the NHS 
budget. This may exclude some of a drug’s added benefit 
from the analysis. Regarding the comparator, using all 
available alternatives provides increased flexibility during 
negotiation processes but can intensify the workload and 
lead to market access delays. 
Regarding patients’ participation, it was considered 
critical to involve patients on the definition of real-world 
outcomes. However, some challenges emerged from the 
discussion, such as the moment and methods of partici-
pation. Participants also suggested the use of multicriteria 
decision analysis to reflect the perspective of multiple 
stakeholders in the pharmacoeconomic assessment. 
Assessing Drugs with Immature or Incomplete Data 
and Drug Reassessments. According to the young profes-
sionals, the use of immature or incomplete data to access 
drugs might result in earlier access to therapies but this 
comes with great uncertainty. They reported that drug 
reassessments are essential for several reasons, i.e., they 
might mitigate the efficacy-effectiveness gap, and they 
may be used to support value-based pricing and improve 
NHS budget management. Participants also suggested 
the validation of surrogate markers. 
Assessing Drug Combinations, Cell and Gene Thera-
pies, and Orphan Drugs. Although drug combinations 
might provide an incremental benefit in comparison with 
monotherapy, they might be methodologically challeng-
ing, i.e., in situations where drugs are from different com-
panies and in cases in which combinations are not cost-
effective, although single therapies may have been grant-
ed reimbursement.
When assessing cell and gene therapies and orphan 
drugs, young professionals suggested that a higher cost-
effectiveness threshold be accepted (although with risks 
for the NHS budget), that multicriteria decision analysis 
be used, and that early access programs to gather more 
real-world evidence to support assessments be promoted.
HTA Reshaping Workshop
The workshop gathered 19 HTA Portuguese experts.
Pharmacoeconomic Assessment Guidelines. The iden-
tification of comparators and the evaluation perspective 
were controversial among the participants. The revision 
of national pharmacoeconomic guidelines led to some 
confusion about identification of the relevant compara-
tors and there was some concern about their late commu-
nication to pharmaceutical companies. Participants sug-
gested that it is vital to assure that pharmacoeconomic 
guidelines are clear for the general population. Some sec-
tions of the guidelines require more detail, such as “other 
costs,” so that they can be quantified (e.g., copayment 
weights). Additionally, they suggest that the reasons for 
approval by the authorities must be clearly stated. The 
need to create a tailored HTA process for medical devices 
was one of the top HTA-wise priorities highlighted by in-
terviewees.
Patients’ Participation. Although it is not clear what 
the best stage of the HTA process is to include the point 
Table 1. Topics discussed in the workshops
HTA Junior Workshop HTA Reshaping Workshop
1. HTA process in Portugal – from 1998 to 2019: are we converging with 
Europe?
2. Assessing drugs with immature data and drug reassessments
3. Assessing drug combos, cell and gene therapies, and orphan drugs
4. MEA and MIP
1. Pharmacoeconomic assessment guidelines
2. How can we include patients in the HTA process?
3. Are we prepared to assess new therapeutic alternatives?
4. How can we assess therapies’ effectiveness in Portugal?
5. Are we ready for new financial and outcome-based agreements (e.g., MEA 
and MIP)?
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Table 2. Main topics addressed in the workshops according to the level of agreement
Suggestions and solutions Main arguments
High level of agreement
It is crucial to expand registries and create a 
national-level registry.
A national-level registry must be created, aggregating all of the data required for 
supporting pharmacoeconomic assessments.
Intercommunication between systems and hospital-level registries is 
fundamental to allow evidence-based decision-making.
The “other costs” section in 
pharmacoeconomic guidelines should be 
clarified.
It is fundamental to clarify which costs should be included in this section as the 
inclusion/exclusion of specific cost elements (e.g., patient out-of-pocket 
expenses) may impact cost-effectiveness assessment and access for patients.
Clarifying what is the impact of these costs in decision-making regarding health 
technologies’ funding is critical.
PRO are a valuable input in pharmaceutical 
reassessments.
Patient participation in the HTA process 
should be “transversal.”
PRO are vital for pharmaceutical reassessments and should also be considered 
in the reimbursement process.
PRO collection will also depend on the creation of registries in order to properly 
collect relevant information.
Patients’ point of view can be implemented along the process, with different 
representatives (e.g., patients, associations, informal caregivers for children/
mental illness, etc.).
There may be a biased outcome evaluation by patients (i.e., self-evaluation) and 
their representatives (e.g., patient associations)
Some patients are not able to answer basic questions for some current 
assessments – more complexity would even be worse.
Moderate level of agreement
In some cases, economic assessments could be 
foregone (e.g., only perform a budget impact 
analysis for “niche” markets such as cell and 
gene therapies).
The standard HTA model can be applied for cell and gene therapies, and there 
are no additional technical challenges (nonconsensual).
Nonetheless, is it worth performing economic assessments for therapies usually 
targeting small population groups, or could a simple budget impact analysis be 
performed?
Outcome-based agreements may be a useful 
mechanism, especially for facilitating patients’ 
access to certain medicines.
MEA such as outcome-based agreements may be an important mechanism to 
ensure quicker and broader patient access to certain medicines.
However, these agreements may not be suitable for “general use” medicines 
(e.g., only for “niche” markets or some hospital therapies mostly used in small 
populations/with limited usage), since implementation difficulties can surpass 
their benefits.
Above all, robust registries are critical to support outcome-based agreements.
MIP may be applied in some cases, i.e., 
whenever there are medicines with variable 
value for different indications.
MIP may be a useful mechanism to apply whenever there is a significant difference 
in outcomes for distinct indications (based on independent assessments for each 
indication, i.e., with different comparators, treatment cost, etc.).
Despite this, MIP may be applicable in some cases; off-label usage and 
difficulties in assuring prescription tracking can be a serious challenge and 
hinder its implementation.
Interoperability between current (and future) 
registries and systems is critical and should be 
improved in the mid-term.
Interoperability between systems and current/future registries is critical for 
registries to function properly and to develop a national-level registry database.
Nevertheless, the capacity for improving the interoperability of systems and 
registries in the mid-term is not consensual, mostly due to the lack of qualified 
resources allocated to this purpose
Low level of agreement
Outcomes-based agreements could be 
performed directly with hospitals (or hospital 
clusters) instead of being established with 
INFARMED.
Although it may be especially useful and applicable to medicines targeting small 
populations (e.g., gene or cell therapies) or “niche” markets, most stakeholders 
believe that the implementation difficulty would be too high for achieving the 
expected benefits of applying this approach.
Moreover, establishing these agreements with a single entity (i.e., INFARMED) 
may already be challenging, and thus the complexity of having more entities 
(i.e., hospitals or hospital clusters) directly negotiating these agreements with 
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of view of patients, it was agreed that their participation 
should be encouraged at the PICO and clinical assess-
ment phases. A lower consent was reached regarding the 
participation of patients at other stages of the HTA pro-
cess. This requires the definition of representativeness 
criteria and the development of proper tools and meth-
odologies to capture and/or quantify PRO. 
New Therapeutic Alternatives. New therapeutic alter-
natives present great uncertainty regarding therapeutic 
and economic outcomes. This could be addressed through 
the design of a national registry for usage and monitoring 
of health technologies. This registry should include hos-
pital-based and population-based information that would 
permit evaluation of innovative technologies. Increasing 
international collaboration and information sharing was 
considered crucial for assessing new therapies, mostly 
due to their often small target populations. 
How Can We Assess Therapies’ Effectiveness in Portu-
gal? The experts identified the need for a national strategy 
for registries. Current registries (e.g., Registo Oncológico 
Nacional [RON], ReumaPT, and SI.VIDA) must be im-
proved and integrated, with a clear and transparent gov-
ernance (e.g., regarding ownership and access). With re-
gard to reassessments, they are dependent on the defini-
tion of clear criteria, timings, and outcomes to be 
measured.
Are We Ready for New Financial and Outcome-Based 
Agreements? Stakeholders referred that Portugal might 
not be fully prepared to implement new outcome-based 
agreements. However, MEA with outcome-based pay-
ments could be feasible to implement at the hospital level, 
with distinct clinical outcomes.
There was a relatively low consensus regarding MIP. 
Some participants referred that, despite comprising mul-
tiple challenges (e.g., prescription tracking, access, and 
ethical concerns), it may be viable in cases where the same 
drug has a significantly different value (outcomes) in dis-
tinct indications. 
There was a low level of agreement regarding the pos-
sibility of establishing outcome-based agreements per-
formed directly with hospitals (or hospital clusters) in-
stead of being established with INFARMED. Although it 
may be especially useful and applicable to medicines tar-
geting small populations, most stakeholders believe that 
the implementation would be quite difficult; moreover, 
establishing these agreements with more than 1 entity 
might add complexity to the process.
This final topic in the expert workshop had a signifi-
cant degree of overlap with the young professionals’ dis-
cussion on MEA and MIP. It is noticeable that the young 
professionals’ insights were significantly aligned with 
HTA Portuguese experts’ point of view, with no major 
point of disagreement or disruption between them.
Discussion
The research reported here aimed to review interna-
tional experiences and establish a consensus based on ex-
pert opinion regarding future challenges in HTA and ac-
cess of patients to new therapeutic alternatives in Portu-
gal. The research comprised 3 phases, i.e., (1) mapping 
and evaluation of different HTA frameworks across Eu-
rope, (2) conduction of in-depth interviews of relevant 
stakeholders, and (3) development of 2 workshops for 
young professionals and relevant stakeholders.
Results for the review on the European frameworks 
showed that the purpose and sophistication of HTA 
frameworks varies across jurisdictions. For example, the 
level of economic evidence required is not the same in all 
countries, and reimbursement agreements also vary con-
siderably. Despite most interviewees agreeing that the 
current HTA process design in Portugal is state of the art 
compared to other European countries, the recent change 
from a societal to an NHS perspective in Portuguese phar-
macoeconomic guidelines was not seen as positive. It was 
acknowledged, however, that the societal perspective 
presents some methodological challenges. 
All of the stakeholders agreed that having patients’ 
point of view in the HTA process is crucial and provides 
added value. However, leveraging PRO comprises some 
challenges, especially regarding data gathering and mon-
itoring. The need to create a tailored HTA process for 
medical devices was one of the top HTA priorities high-
lighted by the interviewees. Drug reassessments should 
be mandatory, despite the need for real-world evidence, 
and required data gathering may entail a significant chal-
lenge. The applicability of MEA and alternative pricing 
strategies gathered moderate agreement across the inter-
viewees. MIP might be a useful resource, but its imple-
mentation is quite difficult due to prescription tracking 
needs and ethical concerns about patient discrimination. 
The requirement for the assessment of drug combina-
tions might present several challenges, i.e., when more 
than 1 company is involved. 
The added value of a drug will be dependent on various 
criteria included in pharmacoeconomic evaluations 
(among them study perspective and the chosen compara-
tor), and this will impact the reimbursement decision. 
The change in Portuguese guidelines contributed to an 
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apparent divergence with European HTA frameworks. 
However, it is acknowledged that difficulties arise in har-
monization of HTA across Europe, given country hetero-
geneity with respect to healthcare budgets and standards 
of care.
Most interviewees identified the inexistence of ade-
quate registries and national level registries as a barrier to 
improved HTA. The development of registries and the 
generation of real-world evidence can be achieved by 
working with clinicians, patients, and regulators. Infor-
mation systems based on electronic health records, as well 
as information and communication technologies, can 
provide a means to overcome the administrative costs as-
sociated with MEA and MIP. It is vital to create a nation-
al level registry, aggregating all of the data required for 
supporting pharmacoeconomic assessments. Intercom-
munication between systems and hospital level registries 
is fundamental to allow evidence-based decision making. 
Although there have been frequent discussions in sci-
entific and professional meetings regarding the future of 
HTA in Portugal, we were unable to find published stud-
ies that used qualitative methods to uncover stakeholder 
opinions regarding the problem at hand. There are, how-
ever, recent international examples of this broad line of 
research. 
Kristensen et al. [28] reported the work of an ISPOR 
(International Society for Health Economics and Out-
comes Research) HTA Council Working Group to pro-
vide guidance on good practices in the use of evidence to 
inform population-based healthcare decision-making for 
pharmaceuticals and other health technologies. They 
drew on literature reviews and expert opinions and con-
cluded that, although many good practices have been de-
veloped, there are also areas where good practices are 
lacking, i.e., in defining the organizational aspects of 
HTA, the use of deliberative processes, and measurement 
of the impact of HTA. 
O’Rourke et al. [29] reported on a survey of members 
of INAHTA (International Network of Agencies for 
Health Technology Assessment – a network of 50 pub-
licly funded HTA agencies). The survey was aimed at 
gathering perspectives from agency leadership on the 
most important issues in HTA today. Among the top 10 
challenges identified were the need to design better ap-
proaches to stakeholder involvement, the pressure to 
evolve existing HTA methods and processes, the scarcity 
of human resources to conduct HTA, and the inadequacy 
of data management systems and having no centralized 
database across public healthcare institutions. Overall, 
these findings are in accordance with those reported in 
the current paper and show that the challenges faced in 
Portugal are similar to those faced in other countries, 
thereby suggesting that much can be learned from an in-
ternational experience.
Trowman et al. [30] summarized the discussions at the 
HTAi (Health Technology Assessment International) 
Global Policy Forum meetings over the last 2 years by 
pointing to key issues perceived by senior HTA users and 
producers. Among the issues discussed were internal and 
external stakeholder involvement in HTA processes, with 
the former comprising the HTA workforce, patients, and 
clinicians and the latter the general public, regulatory 
agencies, and the judiciary. Other key issues were global-
ization of HTA, transferability and harmonization, the 
use of real-world evidence and other data issues, afford-
ability, and rapid indication change/expansions of new 
technologies. Once again, this article shows that much 
can be gained by being alert to how international agencies 
are handling current and future challenges.
Our study has several limitations. First, the workshops 
and the interviews were based on an interview topic guide 
that might be subject to bias. However, this potential bias 
was minimized since an initial effort was made to review 
the literature and finding current hot discussion topics in 
HTA across European countries. This allows for minimi-
zation of the bias in opinion gathering. A second limita-
tion is that we focused mainly on economic topics, in-
cluding economic evaluation and pricing and contractual 
mechanisms, rather than encompassing the full range of 
HTA approaches, particularly clinical, epidemiologic, 
and ethical questions. Third, in hindsight, our 2 work-
shops only considered 1 overlapping topic, i.e., MEA and 
MIP. As it turned out, there was considerable agreement 
in the opinions of young professionals and established 
experts. Future research might consider a greater degree 
of overlap in topics in order to contrast the 2 perspectives. 
Finally, it is acknowledged that our results suffer from a 
lack of generalizability. In-depth interviews and work-
shops were conducted in small groups chosen from rele-
vant stakeholders, and random sampling methods were 
not used. Nevertheless, the interviewees and workshop 
participants were selected from different representative 
sectors, given their important role in the HTA process in 
Portugal, in the present or in the recent past, and thus 
their input and expertise is of great relevance. 
This study also has some strengths. Our approach was 
to develop different depths of analysis, beginning with a 
review of the literature apropos European HTA frame-
works and then moving on to in-depth interviews of rel-
evant stakeholders and, finally, discussion of the results 
Pereira/Alves/Rodrigues/Caetano/Brito-
Cruz/Sousa/Barata
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in 2 different workshops bringing together participants 
with different levels of expertise – on the one hand the 
viewpoints of relevant stakeholders, who represent the 
core of HTA in Portugal, and on the other the opinion of 
younger professionals, who might bring a degree of nov-
elty and innovation to HTA discussions.
The most interesting aspect of this study is the use of 
qualitative methods to gather expert opinions. Despite 
being commonly used in the health arena, it is surprising 
how little such methods have been applied in HTA dis-
cussions. Qualitative methods allow the detailed explora-
tion of issues, particularly in relation to complex phe-
nomena about which informants may have deeply held 
beliefs, and they are particularly useful where the concern 
is to understand the views expressed [11, 31, 32]. The in-
depth interviews carried out provided detailed informa-
tion that could not be reasonably obtained with other 
methods. Interviewing is particularly useful for under-
standing factors underlying particular beliefs and moti-
vations behind behavior, decision-making, and the con-
text for particular occurrences [11, 31, 32]. The 2 work-
shops, carried out in a structured manner, provided the 
ability to access professionally contextualized informa-
tion and to ascertain shared knowledge and values. The 
opportunity for discussion allowed for confrontation of 
different perspectives and promotion of logical consen-
sus. Our approach is akin to an extended focus group 
[12]. Focus groups, in the extended form of a workshop, 
are helpful in identifying the thinking, perceptions, and 
impressions of a particular group. They can yield a great 
deal of informative data but which are not readily gener-
alizable [13]. It would be useful if future research took our 
approach further to better understand and prepare for 
future challenges in HTA and decision-making. 
In conclusion, our study shows that the Portuguese 
HTA framework might be further adapted to upcoming 
challenges and evolve to improve access to innovative 
therapies. There is still a long path to follow towards con-
vergence of HTA frameworks across Europe, but practi-
tioners and decision makers can better adapt to change by 
drawing on international experience and listening to in-
formed opinions of other stakeholders in the HTA pro-
cess.
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